Mean serum E2 is significantly low with significant increase of Serum OST and Calcium in Cases than Control (E2; 43.40pg/ml vs 162.82pg/ml, OST; 15.87ng/ml, Calcium; 14.57mg/dl vs 8.37mg/dl). Significant negative correlation exists between Serum E2 and OST in both cases and control (cases ; r value =-0.628, p value =0.001, control; r=-0.314, p= 0.026).Serum E2 is significantly more low with significant more increase of Serum OST and Calcium in Cases with positive history of joint pain (N=26) than with negative history ( N=24) (E2; Mean ± SD: 38.80±19.00 vs 48.37±22.03,OST; Mean ± SD: 19.22±6.76vs 12.25±7.00,Calcium; Mean ±SD:15.90±3.49 vs 13.12±3.23). Cases with positive history of fracture (N=6) also have more reduction of serum E2, with more increase of Serum OST and Calcium than with negative history (N=44) (E2; Mean±SD:22.50±6.12 vs 46.25±20.56, OST; Mean±SD:25.26±4.34 vs 14.59±7.12, Calcium; Mean±SD:17.14±3.98 vs 14.22±3.47). Cases with positive history of Calcium intake (N=13) have significant increase of Serum OST and Calcium than with negative history (N=37) (OST; Mean±SD:23.24±5.27 vs 13.29±6.65, Calcium: Mean ±SD: 16.43±3.76vs13.91±3.38).
In menopausal women, serum 17β-Estradiol (E2) is lowered as a result failing ovarian function. This decline is associated with increased Osteocalcin level, suggesting clear correlation between serum 17β-Estradiol (E2) and serum Osteocalcin. So they can be considered as biochemical markers osteoporosis in menopausal women. However, larger study is required to arrive at concrete conclusion.